Improved expression of surface-displayed antigens
AssigneeInprother Aps
InventorsAnne-Marie Carola ANDERSSON, Peter Johannes HOLST, Emeline RAGONNAUD, Lasse NEUKIRCH
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition comprising a transfection agent and an mRNA which encodes at least a human endogenous retrovirus (HERV) envelope protein or an immunogenic part thereof with a mutation in the immune-suppressive domain (ISD) that reduces its immunosuppressive property. The present invention also relates to the use of this composition in the manufacture of medicaments and in therapeutic and prophylactic treatment.
Claims26
A composition comprising a transfection agent and an mRNA which encodes at least a human endogenous retrovirus (HERV) envelope protein or an immunogenic part thereof;
- wherein said HERV envelope protein comprises an immune-suppressive domain (ISD) wherein said human endogenous retrovirus (HERV) is HERV-K and wherein the HERV Env protein comprises a mutated immune-suppressive domain (ISD), wherein the ISD mutation is selected from Q525A, L522A, A523Q, N524A, N527A, L529A, R530A, Q531A and T532A;
- and/or
- wherein the HERV envelope protein comprises amino acid mutation S190C.
4-7. (canceled)
(canceled)
(canceled)
(canceled)
21-24. (canceled)
(canceled)
(canceled)
A DNA molecule encoding an mRNA which encodes at least a human endogenous retrovirus (HERV) envelope protein or an immunogenic part thereof;
- wherein said HERV envelope protein comprises an immune-suppressive domain (ISD), wherein said human endogenous retrovirus (HERV) is HERV-K and wherein the HERV Env protein comprises a mutated immune-suppressive domain (ISD), wherein the ISD mutation is selected from Q525A, L522A, A523Q, N524A, N527A, L529A, R530A, Q531A and T532A;
- and/or
- wherein the HERV envelope protein comprises amino acid mutation S190C.
A virus like particle (VLP) comprising a HERV envelope protein, wherein said HERV envelope protein comprises an immune-suppressive domain (ISD), wherein said human endogenous retrovirus (HERV) is HERV-K and wherein the HERV Env protein comprises a mutated immune-suppressive domain (ISD), wherein the ISD mutation is selected from Q525A, L522A, A523Q, N524A, N527A, L529A, R530A, Q531A and T532A;
- and/or
- wherein the HERV envelope protein comprises amino acid mutation S190C.
Dependencies are inferred from the claim text.